VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - July 6, 2006) - WEX Pharmaceuticals Inc. (the "Company") (TSX:WXI) is pleased to announce that the detailed analysis of the Phase IIb/III data collected during the double-blind, randomized, placebo controlled study of TectinTM in inadequately controlled moderate to severe cancer pain is progressing.
